Clinical Trials Directory

This study has three parts: 1. Getting Ready (Screening) - Takes up to 28 days - You'll get blood tests, a tissue sample, a TB test, and health checkups like scans and heart tests. 2. Treatment (Study Dosing) - People are grouped by race - You'll be randomly picked to get either regular chemo or chemo plus a study medicine (tocilizumab) - Medicine is given every 4 weeks - You'll keep doing health checkups and answer questions. 3. After Treatment (Follow-up) - Happens within 30 days after your last dose - More health checkups and questions to see how you're doing.

We are doing this study to collect breath samples to develop an experimental breath test that aims to detect breast cancer at its earliest stages. Additionally, we will look into whether a person's "breath signature" changes before and after they have undergone surgery for breast cancer.

In this study, people will take a medicine called R289 by mouth once or twice a day. The study has two parts: one part is to find the best dose, and the other part is to test two different doses. You may take the medicine at home or at the clinic. You will visit the clinic regularly for tests like blood work, physical check-ups, and heart exams. Some visits may take up to 8 hours. You can stay in the study as long as the medicine is helping and the side effects are not too strong.

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.

We are doing this study to find the most effective, safe dose of an experimental drug called visugromab (CTL-002 - the study drug). We want to find out how beneficial this drug is when it is used in combination with immunochemotherapy for people with metastatic non-squamous non-small cell lung cancer.

We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.

We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.

We are doing this study to find out if an experimental drug called CC-92480 (the study drug) is a safe and effective treatment for multiple myeloma. We also want to figure out the most appropriate dose and schedule for giving the study drug to multiple myeloma patients.